# Asylia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/asylia-therapeutics

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.asyliatx.com
- Total disclosed funding: $15M
- Latest round: Series A (May 25, 2021)
- Investors on record: 1

## About

Based in Texas, US, and founded in 2019, Asylia Therapeutics, Inc. operates as a biotechnology company that develops novel immune-modulating therapies for cancer and auto-immune diseases. The company was co-founded by Richard Jones, Robert Z. Orlowski, Ronald A. DePinho. In May 2021, Asylia Therapeutics raised USD 14.5 million in Series A funding led by Sporos Bioventures.

Asylia Therapeutics, Inc. provides ASY-77A, a novel antibody that allows the extracellular form of Heat Shock Protein (HSP)-70. ASY-77A is antigen-agnostic and has potential in a variety of tumor types such as breast and colon cancer. HSP70 focuses on shuttling tumor-derived antigens to dendritic cells (DCs) and deliver antigens to the immune system of the patients.

Asylia Therapeutics, Inc. plans to use its Series A funding to bring its multiple assets to first-in-human clinical trials for oncology and at the same time potentially generate proof-of-concept signals in auto-immune diseases such as lupus.

## Funding rounds

- Series A, May 25, 2021, $15M — Sporos Bioventures

## Investors

- Sporos Bioventures (https://capitalatlas.ai/funds/sporos-bioventures) — Series A